Topline results reported in phase 2 trial of Clearside’s CLS-TA with Eylea in DME

A phase 2 clinical trial of suprachoroidal CLS-TA with Eylea met its primary endpoint of mean improvement in best corrected visual acuity in patients with diabetic macular edema, Clearside Biomedical announced in a press release.
The multicenter, randomized, masked, controlled TYBEE trial included 71 patients randomly assigned to receive either quarterly treatments of suprachoroidal CLS-TA together with intravitreal Eylea (aflibercept, Regeneron) or four monthly treatments of Eylea with a sham suprachoroidal procedure, the release said. At 6 months, patients in the combination arm gained an